Breakthrough bacteremia by linezolid-susceptible Enterococcus faecalis under linezolid treatment in a severe polytrauma patient

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 6411-6412

  Arena, Fabio ^a   Giani, Tommaso ^a   Galano, Angelo ^a   Pasculli, Marcello ^b   Peccianti, Valeria ^b   Cassetta, Maria Iris ^c   Novelli, Andrea ^c   Rossolini, Gian Maria ^a,d,e  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; LINEZOLID; MEROPENEM;

ADULT; BACTEREMIA; BLOOD CULTURE; BLOOD SAMPLING; BODY MASS; BRAIN EDEMA; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG SENSITIVITY; ENTEROCOCCUS FAECALIS; GLASGOW COMA SCALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOTHERMIA; INTENSIVE CARE UNIT; LETTER; LEUKOCYTE COUNT; LEUKOCYTOSIS; LUNG LAVAGE; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE TRAUMA; PRIORITY JOURNAL; SKULL FRACTURE; SUBDURAL HEMATOMA; URINE CULTURE;

ACETAMIDES; ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; MALE; OXAZOLIDINONES;

EID: 84887462863     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01112-13     Document Type: Letter

References (8)

1. Eliopoulos GM, Wennersten CB, Gold HS, Moellering RC. 1996. In vitro activities in new oxazolidinone antimicrobial agents against enterococci. Antimicrob. Agents Chemother. 40:1745-1747.
2. Livermore DM. 2003. Linezolid in vitro: mechanism and antibacterial spectrum. J. Antimicrob. Chemother. 51(Suppl 2):ii9 -ii16.
3. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; twenty-third informational supplement. M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. 2003. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin. Pharmacokinet. 42:1411-1423.
5. Morata L, Cuesta M, Rojas JF, Rodriguez S, Brunet M, Casals G, Cobos N, Hernandez C, Martínez JA, Mensa J, Soriano A. 2013. Risk factors for a low linezolid trough plasma concentration in acute infections. Antimicrob. Agents Chemother. 57:1913-1917.
6. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - seventh edition. M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Adembri C, Fallani S, Cassetta MI, Arrigucci S, Ottaviano A, Pecile P, Mazzei T, De Gaudio R, Novelli A. 2008. Linezolid pharmacokinetic/ pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int. J. Antimicrob. Agents 31:122-129.
8. Boselli E, Breilh D, Caillault-Sergent A, Djabarouti S, Guillaume C, Xuereb F, Bouvet L, Rimmelé T, SauxM-C, Allaouchiche B. 2012. Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia. J. Antimicrob. Chemother. 67:1207-1210.